Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma kallikrein (Homo sapiens (Human)) | BDBM283440 (US10023557, Example 92 | US10266515, Example 92 | ...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | 7.5 | n/a |
LIFESCI PHARMACEUTICALS, INC. US Patent | Assay Description A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ... | US Patent US10023557 (2018) BindingDB Entry DOI: 10.7270/Q2BZ6839 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM283440 (US10023557, Example 92 | US10266515, Example 92 | ...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
LIFESCI PHARMACEUTICALS, INC. US Patent | Assay Description The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so... | US Patent US9611252 (2017) BindingDB Entry DOI: 10.7270/Q2930W8S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM283440 (US10023557, Example 92 | US10266515, Example 92 | ...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
ATTUNE PHARMACEUTICALS, INC. US Patent | Assay Description A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ... | US Patent US11021463 (2021) BindingDB Entry DOI: 10.7270/Q21R6TN7 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM283440 (US10023557, Example 92 | US10266515, Example 92 | ...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
ENSCMu | Assay Description A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ... | Bioorg Med Chem 14: 7241-57 (2006) BindingDB Entry DOI: 10.7270/Q2J968P7 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM283440 (US10023557, Example 92 | US10266515, Example 92 | ...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <100 | n/a | n/a | n/a | n/a |
LIFESCI PHARMACEUTICALS, INC. US Patent | Assay Description The test compounds at various concentrations, also prepared by serial dilutions as described above, are added to the test wells. The volume of test c... | US Patent US10023557 (2018) BindingDB Entry DOI: 10.7270/Q2BZ6839 | |||||||||||
More data for this Ligand-Target Pair |